Marker Therapeutics, Inc. (MRKR) Stock

Marker Therapeutics, Inc. (MRKR) is a Healthcare stock trading at $1.39 (as of 2026-08-21), with a market capitalization of $23.09M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Marker Therapeutics, Inc. develops T cell–based immunotherapies and peptide-based vaccine candidates for hematological malignancies and solid tumors in the United States. Its MultiTAA-focused platform includes autologous, allogeneic, and off-the-shelf tumor-specific T cell products, alongside peptide programs such as TPIV100/110 and TPIV200 for breast and ovarian cancers.

Understand Marker Therapeutics, Inc.: how it makes money

Marker Therapeutics develops and commercializes T cell-based immunotherapies and peptide-based vaccines for cancer, using its MultiTAA T cell technology to manufacture tumor-specific T cells that recognize multiple tumor-associated antigens.

The profit model depends on whether MultiTAA T cell and related immunotherapy programs demonstrate clinically meaningful response and durability (for example, objective and complete response rates), which then supports commercialization or other value realization.

Business quality (Weak): Clear clinical efficacy signals are highlighted by objective and complete response metrics, but the dataset details shown here are limited, and the latest quarter shows an operating loss, so outcomes and economics remain uncertain.

Bull case

  • Strong early efficacy signals: Objective Response Rate is shown as 66 percent (and 78 percent in Hodgkin Lymphoma), with Complete Response Rate shown as 50 percent (and 44.4 percent at first assessment).
  • Durability indicators are explicitly tracked: Patients With Continued Response for at Least Six Months is 5, and Patients With Durability of at Least Twelve Months is 3, which supports the focus on longer-lasting benefit.

Bear case

  • Limited scale of the patient counts presented: The figures shown include treated and assessed patient counts that are relatively small (for example, 15 treated non-Hodgkin lymphoma patients and 9 treated Hodgkin lymphoma patients), which can increase uncertainty.
  • Recent economics show significant operating losses: For the latest reported quarter (2026-03-31), operating_margin_pct is -541.8 and revenue_b is listed as 0.0, indicating continued financial pressure.
Valuation — source: SEC EDGAR (first-party)
Price$1.39
Market Cap$23.09M
Price / Book1.90
Price / Sales7.21
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$3.55M
Net Margin-343.0%
Revenue Growth (YoY)-86.9%
EPS Growth (YoY)-69.0%
Financial Health — source: SEC EDGAR
Altman Z-Score-28.60 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderNEA Management Company, LLC ($2.11M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOJuan F. Vera
Employees5
CountryUS
IPO Date2002-07-16

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Biofrontera Inc. (BFRI)
  • Cocrystal Pharma, Inc. (COCP)
  • Neuphoria Therapeutics Inc. (NEUP)
  • Celularity Inc. (CELU)
  • Cyclerion Therapeutics, Inc. (CYCN)
  • Tvardi Therapeutics, Inc. (TVRD)
  • Tempest Therapeutics, Inc. (TPST)
  • KALA BIO, Inc. (KALA)
MRKR earnings history · MRKR institutional & insider holders · MRKR KPIs & operating metrics · MRKR financials · MRKR investor presentations & press releases · MRKR SEC filings · MRKR peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.